OTCPK
Sgioy) said its oral COVID-19 drug S-217622 helped patients achieve resolution of five Omicron-related symptoms faster, compared to placebo, thereby meeting the main goal of a phase 3 part of a phase 2/3 study conducted in Asia.
Majority of these patients were previously vaccinated.
The company noted that the low dose of level is submitted for approval in Japan.
Some hospitals rake in high profits while their patients are loaded with medical debt.
Suryakumar Yadav Overtakes Babar Azam, Becomes No.
2 Ranked T20I Batsman, Mohammad Rizwan Regains Top Spot.